Loading...
•
Jun 30, 2024
Vanda Q2 2024 Earnings Report
Reported a net loss with a revenue increase compared to the previous year.
Key Takeaways
Vanda Pharmaceuticals reported a net loss of $4.5 million for Q2 2024, compared to a net income of $1.5 million in Q2 2023. However, total revenues increased by 10% to $50.5 million compared to Q2 2023.
Total revenues for Q2 2024 were $50.5 million, a 10% increase compared to Q2 2023.
Fanapt® net product sales were $23.2 million, a 4% decrease compared to Q2 2023.
HETLIOZ® net product sales were $18.7 million, a 15% decrease compared to Q2 2023 due to generic competition.
PONVORY® net product sales were $8.6 million in the second quarter of 2024.
Forward Guidance
Vanda reinstates financial guidance and expects to achieve the following financial objectives in 2024:
Positive Outlook
- Total revenues are expected to be between $180 to $210 million.
- Year-end cash is expected to be between $360 to $390 million.
- Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024
- PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024
- Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024
Challenges Ahead
- Net loss was $4.5 million in the second quarter of 2024
- HETLIOZ® net product sales decreased 15% due to generic competition
- The FDA provided a preliminary notice that deficiencies preclude discussion of labeling for Tradipitant
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...